Effect of metformin on cancer risk and treatment outcome of prostate cancer: A meta-analysis of epidemiological observational studies

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Yu, Hongliang ^a   Yin, Li ^a   Jiang, Xuesong ^a   Sun, Xiujin ^a   Wu, Jing ^a   Tian, Hao ^a   Gao, Xianshu ^b   He, Xia ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN;

ARTICLE; BIOCHEMICAL RECURRENCE; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; DRUG EFFICACY; DRUG USE; HUMAN; MEDICAL PARAMETERS; META ANALYSIS; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROSTATE CANCER; RETROSPECTIVE STUDY; RISK REDUCTION; TREATMENT OUTCOME; MALE; PATHOLOGY; PROSTATIC NEOPLASMS; PUBLISHING; RISK FACTOR; TUMOR RECURRENCE;

HUMANS; MALE; METFORMIN; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; PUBLICATION BIAS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84919922750     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0116327     Document Type: Article

References (42)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Papanas N, Maltezos E, Mikhailidis DP (2009) Metformin: diamonds are forever. Expert Opin Pharmacother 10: 2395-2397.
3. Kourelis TV, Siegel RD (2012) Metformin and cancer: new applications for an old drug. Med Oncol 29: 1314-1327.
4. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, et al. (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27: 3297-3302.
5. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, et al. (2008) The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27: 3576-3586.
6. Murtola TJ, Tammela TL, Lahtela J, Auvinen A (2008) Antidiabetic medication and prostate cancer risk: a population-based case-control study. Am J Epidemiol 168: 925-931.
7. Onitilo AA, Stankowski RV, Berg RL, Engel JM, Glurich I, et al. (2013) Type 2 diabetes mellitus, glycemic control, and cancer risk. Eur J Cancer Prev.
8. Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, et al. (2012) Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care 35: 119-124.
9. Wright JL, Stanford JL (2009) Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 20: 1617-1622.
10. Spratt DE, Zhang C, Zumsteg ZS, Pei X, Zhang Z, et al. (2013) Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 63: 709-716.
11. Azoulay L, Dell'Aniello S, Gagnon B, Pollak M, Suissa S (2011) Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev 20: 337-344.
12. Patel T, Hruby G, Badani K, Abate-Shen C, McKiernan JM (2010) Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. Urology 76: 1240-1244.
13. Kaushik D, Karnes RJ, Eisenberg MS, Rangel LJ, Carlson RE, et al. (2014) Effect of metformin on prostate cancer outcomes after radical prostatectomy. Urol Oncol 32: 43 e41-47.
14. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, et al. (2010) Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 3: 1451-1461.
15. Soranna D, Scotti L, Zambon A, Bosetti C, Grassi G, et al. (2012) Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 17: 813-822.
16. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, et al. (2013) Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One 8: e71583.
17. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Available: http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp. Accessed 2011 Mar 19.
18. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
19. Dong JY, He K, Wang P, Qin LQ (2011) Dietary fiber intake and risk of breast cancer: a meta-analysis of prospective cohort studies. Am J Clin Nutr 94: 900-905.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
21. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
22. Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52: 1766-1777.
23. Ferrara A, Lewis JD, Quesenberry CP, Jr., Peng T, Strom BL, et al. (2011) Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care 34: 923-929.
24. Hsieh MC, Lee TC, Cheng SM, Tu ST, Yen MH, et al. (2012) The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res 2012: 413782.
25. Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, et al. (2013) Metformin Use and All-Cause and Prostate Cancer-Specific Mortality Among Men With Diabetes. J Clin Oncol 31: 3069-3075.
26. Morden NE, Liu SK, Smith J, Mackenzie TA, Skinner J, et al. (2011) Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care 34: 1965-1971.
27. He XX, Tu SM, Lee MH, Yeung SC (2011) Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol 22: 2640-2645.
28. Margel D, Urbach D, Lipscombe LL, Bell CM, Kulkarni G, et al. (2013) Association between metformin use and risk of prostate cancer and its grade. J Natl Cancer Inst 105: 1123-1131.
29. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, et al. (2012) Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 35: 299-304.
30. Allott EH, Abern MR, Gerber L, Keto CJ, Aronson WJ, et al. (2013) Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. Prostate Cancer Prostatic Dis.
31. Rieken M, Kluth LA, Xylinas E, Fajkovic H, Becker A, et al. (2013) Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer. World J Urol.
32. Tseng CH (2011) Diabetes and risk of prostate cancer: a study using the National Health Insurance. Diabetes Care 34: 616-621.
33. Zannella V, Dal Pra A, Muaddi H, McKee T, Stapleton S, et al. (2013) Reprogramming Metabolism with Metformin Improves Tumor Oxygenation and Radiotherapy Response. Clinical cancer research: an official journal of the American Association for Cancer Research.
34. Preston MA, Riis AH, Ehrenstein V, Breau RH, Batista JL, et al. (2014) Metformin Use and Prostate Cancer Risk. Eur Urol.
35. van Staa TP, Patel D, Gallagher AM, de Bruin ML (2012) Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. Diabetologia 55: 654-665.
36. Qiu H, Rhoads GG, Berlin JA, Marcella SW, Demissie K (2013) Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus. Diabetes Obes Metab 15: 349-357.
37. Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, et al. (2010) Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 53: 1838-1845.
38. Uchio EM, Aslan M, Wells CK, Calderone J, Concato J (2010) Impact of biochemical recurrence in prostate cancer among US veterans. Arch Intern Med 170: 1390-1395.
39. Noto H, Goto A, Tsujimoto T, Noda M (2012) Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One 7: e33411.
40. Grimes DA, Schulz KF (2002) Bias and causal associations in observational research. Lancet 359: 248-252.
41. Penney KL, Stampfer MJ (2013) The time is ripe for a randomized trial of metformin in clinically localized prostate cancer. J Clin Oncol 31: 3054-3055.
42. Rothermundt C, Hayoz S, Templeton AJ, Winterhalder R, Strebel RT, et al. (2014) Metformin in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Phase 2 Trial (SAKK 08/09). Eur Urol.